

Joint Event

4th EUROPEAN BIOPHARMA CONGRESS

&

6th International Conference and Exhibition on PHARMACOLOGY AND ETHNOPHARMACOLOGY

November 09-11, 2017 Vienna, Austria

Structure- and ligand-guided screening of LptA inhibitors: An initial study for developing novel Neisserial antibacterials

Abi Sofyan Ghifari

University of Western Australia, Australia

Pathogenic Gram-negative bacteria such as *Neisseria meningitidis* and *Neisseria gonorrhoeae* have developed resistance against antibiotics due to their ability in creating an envelope on the outer layer of lipooligosaccharides (LOS). The cationic phosphoethanolamine (PEA) decoration of LOS' lipid A is regulated by lipid A-PEA transferase A (LptA) which may serve as a prominent target for developing new antibiotics. The discovery of Neisserial LptA has provided a structural aspect to its catalytic mechanisms and ligand recognition that are crucial for inhibitor development. A combination of structure- and ligand-based approach has been employed to explore novel potent LptA inhibitors among millions of commercially-available compounds and approved drugs. A total of 4000 hit molecules obtained from LIDAEUS structure-based screening and PubMed ligand similarity search were further examined through semi-flexible docking simulation performed in MOE and Schrödinger's Glide. Best hits were therefore carefully selected based on their docking score, drug likeness, and pharmacological properties. Free energy of binding calculation and ligand interaction analysis suggest that the selected 20 hit compounds have a stronger binding affinity than LptA natural substrate and possess a more effective interaction with catalytically-essential residues. Further molecular dynamics (MD) simulation of these 20 compounds also confirms that they all maintained stable complex conformation showing low total RMSD, capability to maintain interactions with active site, and acceptable Ramachandran plot. This study provides an insight to drug repurposing which may serve as an initial step to develop novel potent LptA inhibitors to combat the virulence of multi-drug resistant *Neisseria*.

abi.ghifari@gmail.com